logo

For the Inventor, By the Inventor

Berkshire, United Kingdom

Sterix Limited


USPTO Granted Patents = 51

% Expired Patents = 70.6


Forward Citations = 149

Loading Chart...
Loading Chart...

51 inventors (with patents filed for the assignee):

goldMedal Michael John Reed (45 out of 59 patents)

silverMedal Barry Victor Lloyd Potter (41 out of 45 patents)

bronzeMedal Atul Purohit (19 out of 23 patents)

4.  Lok Wai Lawrence Woo (13 out of 15 patents)

5.  Christian Bubert (7 out of 7 patents)

6.  Matthew Paul Leese (6 out of 6 patents)

7.  Olaf Peters (5 out of 16 patents)

8.  Nigel Vicker (5 out of 8 patents)

9.  Alexander Hillisch (5 out of 41 patents)

10.  Eberhard Unger (5 out of 5 patents)

11.  Christian Gege (4 out of 38 patents)

12.  Gerhard Siemeister (4 out of 77 patents)

13.  Oliver Brook Sutcliffe (4 out of 4 patents)

14.  Barry Victor Potter (4 out of 10 patents)

15.  Bertrand Leblond (3 out of 23 patents)


Core Competencies:
Aromatase Inhibitors
Steroid Sulphatase
Anti-Tumor Compounds
Endocrine-Dependent Tumors
Heterocyclic Compounds
Sulfamic Acid Esters
Polycyclic Sulphamate
Steroidal Compounds
Cell Cycling Inhibition
Estrogen Derivatives
Thioether Sulphamate Steroids

51 patents:

1. 8846737 - Compound (2014-09-30),
2. 8492570 - 2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumor action (2013-07-23),
3. 8470860 - Phenyl-sulfamates as aromatase inhibitors (2013-06-25),
4. 8394825 - Compound (2013-03-12),
5. 8207152 - Methods for treating or preventing cancer by preventing, inhibiting, or arresting cell cycling (2012-06-26),
6. 8148415 - Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity (2012-04-03),
7. 8124614 - Steroidal compounds for inhibiting steroid sulphatase (2012-02-28),
8. 8119627 - Heterocyclic compounds as inhibitors of 17beta-HSD3 (2012-02-21),
9. 8030296 - Oestrogen-17-sulphamates as inhibitors of steroid sulphatase (2011-10-04),
10. 8026229 - Antitumor-active 2-alkoxyestradiol sulfamates (2011-09-27),
11. 8022224 - 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors (2011-09-20),
12. 8003783 - 17B-hydroxysteroid dehydrogenase inhibitors (2011-08-23),
13. 7968561 - Steroidal compounds as steroid sulphatase inhibitors (2011-06-28),
14. 7893284 - Oestrogen derivatives as inhibitors of steroid sulphatase (2011-02-22),
15. RE42132 - Antitumoral D-homoestra-1,3,5(10)-trien-3-yl 2-substituted sulfamates (2011-02-07),
Sterix Limited, based in Berkshire, GB, specializes in the development of innovative cancer treatment solutions. The company focuses on advanced therapeutic areas, particularly in the realm of endocrine-dependent tumors. Its core technologies include aromatase inhibitors and steroid sulphatase, alongside a range of anti-tumor compounds. Sterix is dedicated to addressing complex medical challenges through its expertise in heterocyclic compounds, sulfamic acid esters, and steroidal compounds, contributing to the evolving landscape of oncology.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

51 Patents

#2 in Berkshire

#346 in United Kingdom

#13,753 in the World

Berkshire, GB
Berkshire, United Kingdom

Sterix Limited

Forward Citations = 149

51 inventors:

goldMedal Michael John Reed (45 out of 59 patents)

silverMedal Barry Victor Lloyd Potter (41 out of 45 patents)

bronzeMedal Atul Purohit (19 out of 23 patents)

4.  Lok Wai Lawrence Woo (13 out of 15 patents)

5.  Christian Bubert (7 out of 7 patents)

Please report any incorrect information to [email protected]
Loading…